GlassScriptPhysician profile
Paul S Chang
NPI 1790797280
$24,758.61
in general payments reported to CMS, 2019-2025
40 companies · $19.49 in 2025
The $19.49 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $5,699 · 2021: $3,190 · 2022: $231 · 2025: $19.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $19.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $14,761.15 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $3,661.89 | 2019-2022 | |
| Abbvie INC. | $829.96 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $687.25 | 2019-2022 | |
| Amgen INC. | $524.55 | 2019-2021 | |
| Pfizer INC. | $469.99 | 2019-2021 | |
| Glaxosmithkline, LLC. | $465.00 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $301.45 | 2019-2022 | |
| Allergan, INC. | $286.30 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $285.02 | 2021 | |
| Merck Sharp & Dohme LLC | $269.32 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $262.93 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.80 | 2019-2021 | |
| Medtronic, INC. | $190.30 | 2021 | |
| Amarin Pharma, INC. | $158.03 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.